

癌症類別		肝 癌
Systemic therapy	最近改版日期	115.03
	處方內容	(1)Bevacizumab 5-10mg/kg+Atezolizumab 1200mg (2)Tremelimumab 300mg+ Durvalumab 1500mg/4wks (3)Lenvatinib 10mg/d (視 Performance, Side effects, financial, response 調整劑量) (4)Sorafenib 400-800 mg/d (5)Regorafenib 80-160 mg/d (6)Cabozantinib 60mg/d(Option) (7)Ramucirumab(6 or 8mg/kg) (8)Nivolumab 100-200 mg/3~4wks(Option) (9)Pembrolizumab 100mg/3wks(Option) (10)Nivolumab 120mg + Lpilimumab 50mg/3wks (11)Tislelizumab 200mg/3wks

● Immunotherapy:

PD-1, PD-L1 抑制劑 (如 atezolizumab、nivolumab、Pembrolizumab、avelumab)(109/11/01 健保條例 9.69) 、
Durvalumab (112/12/01 健保條例 9.69))

參考文獻：NCCN Guideline 2026.V1 Hepatobiliary cancers